LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the ...

Patritumab deruxtecan shows meaningful clinical activity in heavily pretreated patients with metastatic breast cancer and ...

Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in ...

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...

Primary Endpoint met: Statistically significant reduction in blood-fat levels after eating (-51.9%) Multiple secondary endpoints met: Including statistically significant reduction in weight regain ...

Spine Biopharma Inc. cited an “inconsistent sham control response” among some of the sites in its phase III study testing SB-01 as an intradiscal treatment for patients with chronic low back pain ...

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 ...